| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bacterial ribosomes (30S subunit). Neamine binds to the bacterial 16S rRNA, causing misreading of the genetic code and inhibition of protein synthesis. It also targets angiogenin, an angiogenic factor, thereby inhibiting angiogenesis.
|
|---|---|
| ln Vitro |
Neamine treatment (0.625-25 μM; 48 hours; AsPC-1 cells) dose-dependently suppresses the proliferation of ANG-mediated AsPC-1 cells in the range of 0.625-25 μM[1]. Neamine (100 μM) also successfully prevents ANG from translocating nuclear[1].
Neamine has antibacterial activity against Gram-positive and some Gram-negative bacteria. As an anti-angiogenic agent, it inhibits angiogenin-induced angiogenesis. Detailed MIC values against specific pathogens are available from specialized databases. It has been extensively studied for its potential therapeutic applications. |
| ln Vivo |
In AsPC-1 xenograft models, neamine (30–60 mg/kg; subcutaneous injection; daily; for 14 days; male Balb/c nude mice) has anti-tumor properties. In tumor xenografts, neamine lowers the expression levels of ANG, Ki-67, and CD31[1].
In vivo activity data for Neamine is not extensively detailed in standard references. As an aminoglycoside antibiotic, it is expected to show efficacy in animal models of bacterial infections. As an anti-angiogenic agent, it may show activity in tumor models. Its in vivo efficacy may be limited by its rapid renal clearance, a characteristic of aminoglycosides. |
| Enzyme Assay |
In vitro antibacterial susceptibility testing is performed using standard broth microdilution methods (CLSI guidelines). The compound is serially diluted in 96-well plates, and bacterial cultures are added. The minimum inhibitory concentration (MIC) is determined.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: AsPC-1 cells Tested Concentrations: 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 25 µM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited angiogenin (ANG)-induced AsPC-1 cells proliferation. In vitro anti-angiogenic activity is assessed using endothelial cell proliferation, migration, and tube formation assays. Human umbilical vein endothelial cells (HUVECs) are treated with Neamine, and angiogenesis is stimulated with angiogenin or VEGF. The inhibition of these processes is quantified. |
| Animal Protocol |
Animal/Disease Models: Male Balb/c nude mice (4 weeks old) injected with AsPC-1 cells[1]
Doses: 30 mg/kg, 60 mg/kg Route of Administration: subcutaneous (sc)injection; daily; for 14 days Experimental Results: Had anti-tumor effects on AsPC-1 xenograft models. In vivo antibacterial efficacy studies are conducted in mouse models of infection (e.g., peritonitis or thigh infection models). Neamine is administered subcutaneously or intramuscularly. Bacterial load in tissues is quantified. For anti-angiogenic studies, mouse models of cancer or angiogenesis are used. |
| ADME/Pharmacokinetics |
Neamine has a molecular weight of 322.36 and a molecular formula of C12H26N4O6. It is soluble in water (100 mg/mL). It is a solid at room temperature. As an aminoglycoside, it has poor oral bioavailability and is typically administered parenterally.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of Neamine are not extensively reported. As an aminoglycoside, it may cause nephrotoxicity and ototoxicity, similar to other drugs in this class. The risk of these toxicities is dose- and duration-dependent. It is used as a research compound, and therapeutic use is limited.
|
| References | |
| Additional Infomation |
Neomycin is a glycosylated 2-deoxy-D-streptomycin with a 6-amino-α-D-glucosamine group attached at the 4-position oxygen atom. It possesses antibacterial activity. It is a 2,6-dideoxy-α-D-glucosinolate, belonging to the aminoglycoside class. It is the conjugate base of neomycin(4+). Neomycin has been reported to exist in Streptomyces fradiae, and relevant data are available. Neomycin is a minor component of the neomycin complex, a broad-spectrum aminoglycoside antibiotic derived from Streptomyces fradiae, possessing antibacterial activity.
Neamine is a research-grade aminoglycoside antibiotic and anti-angiogenic agent. It is used as a tool to study bacterial protein synthesis and angiogenesis. It is not approved for clinical use as a therapeutic agent. Its molecular formula is C12H26N4O6 and its molecular weight is 322.36. |
| Molecular Formula |
C12H26N4O6
|
|---|---|
| Molecular Weight |
322.36
|
| Exact Mass |
322.185
|
| CAS # |
3947-65-7
|
| Related CAS # |
Neamine tetrahydrochloride;15446-43-2
|
| PubChem CID |
72392
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
577.9±50.0 °C at 760 mmHg
|
| Melting Point |
225.5°C (rough estimate)
|
| Flash Point |
303.3±30.1 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.649
|
| LogP |
-2.78
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
378
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O)O)N
|
| InChi Key |
SYJXFKPQNSDJLI-HKEUSBCWSA-N
|
| InChi Code |
InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1
|
| Chemical Name |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1021 mL | 15.5106 mL | 31.0212 mL | |
| 5 mM | 0.6204 mL | 3.1021 mL | 6.2042 mL | |
| 10 mM | 0.3102 mL | 1.5511 mL | 3.1021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
